Eventide Healthcare & Life Sciences Fund Cl C · NASDAQ:ETCHX
Eventide Healthcare & Life Sciences Fund Cl C — Investor Presentation (April 2025)
35 slides from Eventide Healthcare & Life Sciences Fund Cl C's investor presentation, Apr 30, 2025
Slide 1: Eventide Healthcare & Life Sciences Fund Q1 2025 Presentation
Eventide Healthcare & Life Sciences Fund Q1 2025 Presentation 1 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 2: Eventide company overview
Founded: 2008 Headquarters: Boston, MA Vision: To serve individuals, financial advisors, and institutions by offering high performance investments that create compelling value for the global common good. Funds: • Eventide Gilead Fund • Eventide Balanced Fund • Eventide Healthcare & Life Sciences Fun
Slide 3: Eventide Healthcare & Life Sciences Fund
Eventide Healthcare & Life Sciences Fund Objective A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX Seeks to provide long-term capital appreciation. About the Fund A diversified mutual fund seeking long-term capital appreciation in the healthcare and life sciences sectors (≥80%). Concentrates investments i
Slide 4: Eventide Distinctives
Eventide Distinctives Themes of Human Flourishing Seeking to invest in companies positioned to participate in long-term secular investment themes that serve important human needs. Creating Compelling Value for Society and the Global Common Good Focused on identifying and investing in companies capab
Slide 5: Fund Distinctives
Fund Distinctives Focused on Early Development-Stage Companies Median market capitalization of $2.5 billion. Creating Compelling Value For Patients and Society Targeting large unmet medical needs, rare and orphan diseases. Access to Differentiated Offerings Investing in IPOs, mezzanine financing off
Slide 6: Portfolio Management
Portfolio Management Finny Kuruvilla, MD, PhD I-hung Shih, PhD Co-Chief Investment Officer, Portfolio Manager, Senior Portfolio Manager Managing Director Finny Kuruvilla, MD, PhD serves as Co-Chief Dr. Shih serves as Co-Portfolio Manager for the Investment Officer and Senior Portfolio Manager for Ev
Slide 7: Healthcare Research Team
Healthcare Research Team Westley Dupray, Bert Kinsey, CFA PhD, PharmD Research Analyst, Principal Research Analyst, Principal Mr. Dupray serves as a Research Analyst for Dr. Kinsey serves as a Eventide, and a Principal for Research Analyst for Eventide Ventures. He has Eventide, and Principal for re
Slide 8: Investment Team
Investment Team Finny Kuruvilla, Dolores Chris Grogan, I-hung Shih, Andrew Singer, MD, PhD Bamford, CFA CFA PhD CFA Co-CIO, Senior Co-CIO, Senior Portfolio Manager, Portfolio Manager, Portfolio Manager, Portfolio Manager Portfolio Manager Director of Asset Managing Director Senior Research Allocatio
Slide 9: Trading Team
Trading Team Colin Delaney Conor Kelly Head of Trading, Portfolio Trader Specialist 9 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 10: Business 360 Research Team
Business 360® Research Team Tyler Frugia Brock Treworgy, Abel Ballew Portfolio CAMS, CFE Manager, Business 360 Business 360 Director of Research Manager Business 360, Manager Chief Information Officer Jaime Joshua Xavier Raju Business 360 Business 360 Research Research Analyst Analyst 10 For use dur
Slide 11: Investment Philosophy
Investment Philosophy We believe high-quality companies that excel at creating value for others and trade at a discount to intrinsic value offer superior long-term risk-adjusted returns. The Adviser's judgment about the quality and intrinsic value of companies may prove to be incorrect. There is no
Slide 12: Investment Process
Investment Process FINANCIAL A N A LY S I S RISK MANAGEMENT Look for companies with long- term financial strength by Construct portfolio with analyzing historical financial goals of high internal IDEA performance and modeling diversification and low EVENTIDE VA L U AT I O N G E N E R AT I O N future
Slide 13: Idea Generation
Idea Generation Start with themes, then identify companies we believe are best positioned for participation • Understand the big picture of industries. • Discern attractive long-term secular investment themes. • Leverage consultants, industry experts, Key Opinion Leaders. • Review industry specific
Slide 14: Biotech Investment Checklist
Biotech Investment Checklist Compelling data (i.e., differentiated efficacy, toxicity, or route of delivery) ideally from a well-controlled clinical trial or, if preclinical, the molecular target or animal model is well-validated and translatable into humans. Targeting a large unmet medical need
Slide 15: Investment Themes
Investment Themes Themes poised to grow by serving society and human flourishing • Autoimmune • Cardiovascular and Metabolism • Gastroenterology • Infectious Disease • Medical Devices, Tools, and Diagnostics • Neurology • Ophthalmology • Precision Oncology • Rare Disease These are representative exa
Slide 16: Investment Themes
Investment Themes Seeking to invest in companies positioned at the nexus of long- term secular growth themes and important human needs. These are representative examples of themes in the Eventide Funds. We refer to long-term secular investment themes as those that tend to be persistent through marke
Slide 17: Qualitative Analysis
Qualitative Analysis Look for “high-quality” companies, which we believe to have: The Adviser’s judgment about the quality of a particular company may prove to be incorrect. There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. 17 For use
Slide 18: Our Research Framework: Business 360
Our Research Framework: Business 360® Our proprietary framework for evaluating both a company’s long-term competitive advantage and its impact on human flourishing by analyzing its operations and strategy through the lens of key stakeholders. Reference to Eventide’s Business 360® approach is provide
Slide 19: We believe what's right is also smart
We believe what’s right… …is also smart. Companies that place a premium on: Tend to have: • Customer satisfaction • Higher customer loyalty • Employee morale • Higher productivity • Supplier partnership • Resilient supply chains • Societal impact • Stronger brands • Environmental stewardship • Susta
Slide 20: Financial Analysis
Financial Analysis Look for companies with long-term financial strength QUALITIES: Well capitalized (≧ 1 year of cash remaining) to reach key No history of ill-conceived and/or poorly executed milestones (clinical trial data release, FDA indication, product financings (extremely dilutive) launch) Cl
Slide 21: Valuation Analysis
Valuation Analysis Look for companies with most attractive value and potential • Measure intrinsic value through Discounted Cash Flow (DCF) analysis. We believe the best way to measure the • Build DCF model using forecast assumptions and intrinsic value of a company is with then probability-adjust t
Slide 22: Macro Positioning
Macro Positioning Position portfolio according to our macro views • Establish macro views by synthesizing three key data streams: • Leading economic indicators • Valuation • Sentiment • Position portfolio using cash and other tools to allow stock selection on fundamental grounds to mesh with our mac
Slide 23: Portfolio Construction
Portfolio Construction Construct portfolio, manage for risk • Concentrated portfolio that typically holds approximately 60-70 companies (based on conviction level and asymmetry of gain vs. loss). • Manage for risk through high internal diversification and pursuit of consummate knowledge of holdings.
Slide 24: Sell Discipline
Sell Discipline Continuously scrutinize investment case • Investment thesis failure. • No longer meets Eventide’s Business 360® criteria. • Price target achieved. • Management transition or other concerns. • More attractive use of capital elsewhere. For informational purposes only. There is no guara
Slide 25: Composition
Composition A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX 25 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 26: Growth of 10k
Growth of 10k A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX 26 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 27: Trailing Returns
Trailing Returns A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX 27 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 28: Calendar Year Returns
Calendar Year Returns A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX 28 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 29: Market Risk
Market Risk A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX 29 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 30: Important Information
Important Information Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund’s ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in sm
Slide 31: Investment Ideals
Investment Ideals We seek investment We believe in respecting the life and dignity of all people. This means we invest in areas that honor life, opportunities that like treatments seeking to address challenging diseases. This also means we seek to avoid profiting from reflect these ideals: anything
Slide 32: Values-Based Analysis
Values-Based Analysis There are three dimensions to our approach to values-based investing: AV O I D EMBRACE ENGAGE Create an investable Conduct original Business 360® research Engage portfolio companies and universe of securities that to find the highest quality opportunities that security issuers
Slide 33: Sales Team
Sales Team Mark Wambolt Michael Rob Carney Jeff Cave, Lans Slack Head of Schnackenberg Senior Manager, CIMA® Senior Regional Strategic Head of Institutional Senior Regional Director, Mid- Partnerships Institutional Services Director, Atlantic Region Sales Northeast Region Greg Gunter Jacob Seif, Col
Slide 34: Investment Consulting Group
Investment Consulting Group Chris Grogan, Fred Ge, CFA Robert Carney CFA Senior Portfolio Senior Manager, Portfolio Consultant Institutional Manager, Services Director of Asset Allocation Services 34 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Slide 35: Eventide Asset Management, LLC
Eventide Asset Management, LLC | One International Place, Ste. 4210 | Boston, MA 02110 | 877-771-EVEN (3836) 35 For use during Q2 2025 | © Eventide Asset Management, LLC. 20250430-4441243
Eventide Healthcare & Life Sciences Fund — Investor Presentation (April 2025) on 6ix